Auxilium boosts urology business with $585M Actient buy

04/30/2013 | Genetic Engineering & Biotechnology News · Reuters

Auxilium Pharmaceuticals agreed to pay $585 million in cash to purchase urology-treatment-maker Actient Holdings. The deal gives Auxilium access to Actient's testosterone replacement therapies and erectile dysfunction drug. The acquisition "creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio," Auxilium President and CEO Adrian Adams said.

View Full Article in:

Genetic Engineering & Biotechnology News · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT